Shares of Oxford BioDynamics Plc (LON:OBD – Get Free Report) shot up 39% during mid-day trading on Wednesday . The company traded as high as GBX 0.70 ($0.01) and last traded at GBX 0.70 ($0.01). 95,053,336 shares were traded during trading, an increase of 900% from the average session volume of 9,501,976 shares. The stock had previously closed at GBX 0.50 ($0.01).
Oxford BioDynamics Price Performance
The stock has a market capitalization of £1.66 million, a P/E ratio of -8.88 and a beta of 0.42. The business has a fifty day simple moving average of GBX 1.03 and a 200 day simple moving average of GBX 3.01. The company has a current ratio of 0.68, a quick ratio of 2.80 and a debt-to-equity ratio of 370.22.
About Oxford BioDynamics
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
See Also
- Five stocks we like better than Oxford BioDynamics
- Stock Market Upgrades: What Are They?
- Uber’s Business, Cash Flow, and AI are Why it Will Set a New High
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
- What is a Secondary Public Offering? What Investors Need to Know
- These are the 3 Stocks Most Likely to Split in 2025
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
